Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

P van Heteren; AS Ossami; R Michael; B Altmann; A Davies; R Greil; AM García-Sancho; A Kerkoff; F Kroschinsky; FD Vicente; M Hänel; U Schnetzke; A Polowinski; C Köhler; M Ziepert; B Glass

Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

P van Heteren
, AS Ossami
, R Michael
, B Altmann
, A Davies
, R Greil
, AM García-Sancho
, A Kerkoff
, F Kroschinsky
, FD Vicente
, M Hänel
, U Schnetzke
, A Polowinski
, C Köhler
, M Ziepert
, B Glass

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	108-109
Number of pages	2
Journal	Oncology Research and Treatment
Volume	46
Publication status	Published - 2023

Cite this

van Heteren, P., Ossami, AS., Michael, R., Altmann, B., Davies, A., Greil, R., García-Sancho, AM., Kerkoff, A., Kroschinsky, F., Vicente, FD., Hänel, M., Schnetzke, U., Polowinski, A., Köhler, C., Ziepert, M., & Glass, B. (2023). Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL). Oncology Research and Treatment, 46, 108-109.

van Heteren, P ; Ossami, AS ; Michael, R et al. / Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL). In: Oncology Research and Treatment. 2023 ; Vol. 46. pp. 108-109.

@article{7278bfe8c9d64fae917bd45a31b8f4fe,

title = "Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)",

author = "\{van Heteren\}, P and AS Ossami and R Michael and B Altmann and A Davies and R Greil and AM Garc{\'i}a-Sancho and A Kerkoff and F Kroschinsky and FD Vicente and M H{\"a}nel and U Schnetzke and A Polowinski and C K{\"o}hler and M Ziepert and B Glass",

note = "Times Cited in Web of Science Core Collection: 0 Total Times Cited: 0 Cited Reference Count: 0",

year = "2023",

language = "English",

volume = "46",

pages = "108--109",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "Karger ",

}

van Heteren, P, Ossami, AS, Michael, R, Altmann, B, Davies, A, Greil, R, García-Sancho, AM, Kerkoff, A, Kroschinsky, F, Vicente, FD, Hänel, M, Schnetzke, U, Polowinski, A, Köhler, C, Ziepert, M & Glass, B 2023, 'Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)', Oncology Research and Treatment, vol. 46, pp. 108-109.

Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL). / van Heteren, P; Ossami, AS; Michael, R et al.
In: Oncology Research and Treatment, Vol. 46, 2023, p. 108-109.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

AU - van Heteren, P

AU - Ossami, AS

AU - Michael, R

AU - Altmann, B

AU - Davies, A

AU - Greil, R

AU - García-Sancho, AM

AU - Kerkoff, A

AU - Kroschinsky, F

AU - Vicente, FD

AU - Hänel, M

AU - Schnetzke, U

AU - Polowinski, A

AU - Köhler, C

AU - Ziepert, M

AU - Glass, B

N1 - Times Cited in Web of Science Core Collection: 0 Total Times Cited: 0 Cited Reference Count: 0

PY - 2023

Y1 - 2023

M3 - Abstract (Journal)

SN - 2296-5270

VL - 46

SP - 108

EP - 109

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

ER -

van Heteren P, Ossami AS, Michael R, Altmann B, Davies A, Greil R et al. Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL). Oncology Research and Treatment. 2023;46:108-109.